Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$11.90 ▼ -0.88
(-6.89%)
MKT CAP: $657.4M • VOL: 683.5K
52W L $7 52W H $17
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$10
MEDIAN
$13
MEAN
$14
HIGH
$16
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE FDMT TAPE
FDMT // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $14.40 | $13.68 | 2025-02-14 | $10.83 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $14.99 | $14.04 | 2025-02-06 | $11.19 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $13.57 | $13.09 | 2025-01-29 | $11.42 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $12.14 | — | 2025-01-17 | $11.66 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $10.47 | $11.30 | 2025-01-09 | $10.59 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $14.16 | $12.38 | 2024-12-18 | $10.35 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $11.54 | $12.02 | 2024-12-04 | $11.07 | -4.3% | 48% | C |